{"raw_mentions": "There are no sentences that meet the specified criteria, as none of the sentences contain a specific molecule name, a bioactivity metric, a numeric value for that metric, and a unit for that value. The text primarily describes the composition and characteristics of L-asparaginase formulations and enzymes, without providing specific bioactivity data."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nIn an exemplary embodiment, a L-asparaginase formulation is administered intramuscularly every other day over a period of 5 consecutive days followed by a rest period of 2 consecutive days, wherein the amount is about 25 mg/m<sup>2</sup>.\nIn an exemplary embodiment, a L-asparaginase formulation is administered intravenously every other day over a period of 5 consecutive days followed by a rest period of 2 consecutive days, wherein the amount is about 37.5 mg/m<sup>2</sup>.\nIn an exemplary embodiment, a L-asparaginase formulation is administered intravenously every other day over a period of 5 consecutive days followed by a rest period of 2 consecutive days, wherein the amount is about 50 mg/m<sup>2</sup>.\nThe amounts of the L-asparaginase formulation of the present disclosure that are to be delivered will depend on many factors, for example, the IC50, EC50, the biological half-life of the compound, the age, size, weight, and physical condition of the patient, and the disease or disorder to be treated.\nGenerally, the amount of the L-asparaginase formulation of the present disclosure will be administered at a range from about 1 milligram per square meter of the surface area of the patient's body (mg/m<sup>2</sup>) to 1,000/m<sup>2</sup>, with a dosage range of about 10 mg/m<sup>2</sup> to about 100 mg/m<sup>2</sup> to treat disease, including but not limited to ALL or LBL.\nIn some embodiments, the method comprises administering the recombinant L- asparaginase of the present disclosure at an amount from about 10 mg/m<sup>2</sup> and about 100 mg/m<sup>2</sup>.\nIn some embodiments, the method comprises administering the L- asparaginase formulation of the present disclosure at an amount from 10 mg/m<sup>2</sup> and 100 mg/m<sup>2</sup>.\nIn some embodiments, the L-asparaginase formulation of the present disclosure is administered in an amount of about 10,15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 95, or 95 mg/m<sup>2</sup> or an equivalent amount thereof (for example on a protein content basis)."}
{"final_json": [{"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "25", "unit": "mg/m^2"}, {"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "37.5", "unit": "mg/m^2"}, {"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "50", "unit": "mg/m^2"}, {"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": null, "unit": null}, {"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": null, "unit": null}, {"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1", "unit": "mg/m^2"}, {"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1000", "unit": "mg/m^2"}, {"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "10", "unit": "mg/m^2"}, {"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100", "unit": "mg/m^2"}, {"molecule_name": "recombinant L-asparaginase", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "10", "unit": "mg/m^2"}, {"molecule_name": "recombinant L-asparaginase", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100", "unit": "mg/m^2"}, {"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "10", "unit": "mg/m^2"}, {"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100", "unit": "mg/m^2"}, {"molecule_name": "L-asparaginase formulation", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "10,15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 95, or 95", "unit": "mg/m^2"}]}
